Characterization of quinolone resistant genes and control of qnrB transfer by Potentox in clinical isolates

Potentox has enhanced in vitro antibacterial activity compared to other drugs against quinolone resistant clinical isolates. 10 mM EDTA effectively prevents the conjugal transfer of qnrB gene from donor to recipient. When the same concentration of EDTA was used as a solvent for Potentox, it has again inhibited the conjugal transfer of qnrB gene from donor to recipient. Therefore, inhibition of conjugation can be a novel antimicrobial approach to combat spreading of antibiotic resistance which can be achieved only with Potentox the novel antibiotic adjuvant entity (US patent - US8178501B2).